A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
about
Adoptive T cell therapy: Addressing challenges in cancer immunotherapySafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasGeneration of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinomaTrial Watch: Adoptive cell transfer immunotherapy.Calcium Dynamics of Ex Vivo Long-Term Cultured CD8+ T Cells Are Regulated by Changes in Redox Metabolism.Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivoSkewed distribution of IL-7 receptor-α-expressing effector memory CD8+ T cells with distinct functional characteristics in oral squamous cell carcinoma.Optimization manufacture of virus- and tumor-specific T cellsFusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.
P2860
Q24805804-FAAA4339-815E-41A9-B26D-7BBD7E0CFA4FQ29622949-7893DF4F-A323-46E0-A8A5-BA042E4CC4E9Q34122445-B96FCC92-5346-4DFF-8F6C-5A4C8C7220FEQ34616800-B8F3B4FC-E8AB-4870-B0BF-327B6A018736Q35677962-1E6B1D7B-EC19-4B7E-84BC-B97702A00F38Q36057432-098BF84D-CD92-4D67-8037-CD7463CD8B9FQ36104261-0545B175-B26E-49BD-A225-9B9BEBFFA296Q36453843-2FFE0160-3C3C-439B-8F12-F8B3F45CFF34Q37386167-488C9920-77C3-4DEC-BBBB-791D5EC5C2C5Q37509713-F01D4410-609D-4523-A527-440917026967Q37931623-3C8E26F2-B65B-4DFE-8D3C-D04ED1A05620Q38289899-86081F20-72A3-4816-98DC-41DD1767282CQ42079725-ACADFD5F-82F8-41B0-92E6-B5E6E049832AQ42136462-8A53A4E5-A395-413F-AD9B-6DA51A80B3E4Q42198836-FAF8681B-7E3A-4761-8B5C-460C3A815257
P2860
A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A phase I trial of CD3/CD28-ac ...... tastatic renal cell carcinoma.
@en
type
label
A phase I trial of CD3/CD28-ac ...... tastatic renal cell carcinoma.
@en
prefLabel
A phase I trial of CD3/CD28-ac ...... tastatic renal cell carcinoma.
@en
P2093
P1476
A phase I trial of CD3/CD28-ac ...... etastatic renal cell carcinoma
@en
P2093
Christi Sifri-Steele
John A Thompson
Mark W Frohlich
Robert A Figlin
Ronald J Berenson
P304
P407
P433
P577
2003-09-01T00:00:00Z